
A close-up of hands holding a tablet and a pen

Description automatically generated**U.S. Infectious Respiratory Disease Diagnostics Market**

According to Intelli, the U.S. Infectious Respiratory Disease Diagnostics Market size was valued at USD 18,874.1 Million in 2024 and is projected to reach USD 27,305.5 Million by 2032, growing at a compound annual growth rate (CAGR) of 5.22%, during the forecast period of 2024 to 2032.



Infectious respiratory diseases remain a leading cause of global morbidity and mortality, posing serious public health challenges across all age groups and geographies. Caused by a wide array of pathogens, including viruses, bacteria, and fungi, these diseases encompass common conditions such as influenza, pneumonia, tuberculosis, COVID-19, and respiratory syncytial virus (RSV) infections. Their rapid transmission, potential to trigger epidemics or pandemics, and the frequent emergence of drug-resistant strains have amplified the need for timely and accurate diagnostic solutions. Diagnostics represent the first and most crucial line of defense against infectious respiratory diseases, empowering healthcare providers to accurately detect pathogens, evaluate disease progression, and initiate timely, targeted treatments. The field has witnessed a significant evolution from conventional culture techniques and immunoassays to advanced molecular diagnostics and point-of-care testing (POCT), driven by clinical necessity and rapid technological progress. These rapid diagnostic tools not only enhance patient care and recovery but also serve as essential pillars in infection control, disease surveillance, and global public health readiness. As the burden of respiratory pathogens continues to shift with changing climates, urbanization, and population growth, the diagnostics landscape is poised for ongoing transformation. In this context, infectious respiratory disease diagnostics stand at the intersection of clinical medicine, biotechnology, and global health policy, representing not just a tool for disease detection but a cornerstone of effective healthcare delivery and epidemic preparedness.

**U.S. Infectious Respiratory Disease Diagnostics Market Definition**

The U.S. Infectious Respiratory Disease Diagnostics Market refers to the segment of the healthcare and biotechnology industry focused on the development, production, distribution, and application of diagnostic tools and technologies used to detect, identify, and monitor infectious respiratory pathogens. The market includes a broad spectrum of diagnostic technologies, ranging from established methods like molecular diagnostics, A close-up of hands holding a tablet and a pen

Description automatically generatedsuch as RT-PCR and isothermal amplification and immunoassays, including ELISA and lateral flow tests, to traditional microbiological cultures. It also encompasses cutting-edge innovations such as next-generation sequencing (NGS), biosensors, and AI-powered diagnostic platforms. In addition to centralized laboratory systems, the market covers POCT and at-home diagnostic kits, catering to diverse applications in clinical care, public health monitoring, and personal health management.

**U.S. Infectious Respiratory Disease Diagnostics Market Overview**

The U.S. Infectious Respiratory Disease Diagnostics Market is driven by several critical factors that continue to shape its growth and innovation. A major driver is the rising prevalence of infectious respiratory diseases such as influenza, COVID-19, RSV, and pneumonia, which has intensified the demand for early and accurate diagnostic solutions. Technological innovations such as rapid molecular diagnostics, automated testing systems, and AI-integrated platforms are significantly improving the accuracy, speed, and accessibility of respiratory disease diagnostics. The increasing shift toward POCT and home-based diagnostic kits reflects a broader move toward decentralized healthcare, meeting the rising demand for convenience, faster turnaround times, and patient-centered care. Furthermore, substantial government investments, robust public health initiatives, and collaborative efforts among healthcare providers, diagnostic manufacturers, and research institutions are accelerating the development and deployment of advanced diagnostic solutions, further propelling market growth. Heightened awareness of respiratory health, coupled with ongoing investments in public health infrastructure and pandemic preparedness, further fuels the adoption of innovative diagnostic solutions across clinical and non-clinical settings.

**U.S. Infectious Respiratory Disease Diagnostics Market Segmentation**

The U.S. market for infectious respiratory disease diagnostics is segmented based on technology, disease type, and end user, allowing for a comprehensive analysis of growth trends and demand drivers across different segments.

**U.S. Infectious Respiratory Disease Diagnostics Market, By Technology**

* A close-up of hands holding a tablet and a pen

  Description automatically generated**Molecular Diagnostics**
* **Immunoassays**
* **Microbiological Culture Techniques**
* **Biosensors and Nanotechnology-Based Diagnostics**
* **Next-Generation Sequencing (NGS)**
* **Artificial Intelligence and Machine Learning-Based Platforms**

In the U.S. Infectious Respiratory Disease Diagnostics Market, molecular diagnostics lead the technology landscape, driven by the widespread use of RT-PCR and other nucleic acid amplification methods known for their speed, accuracy, and reliability, especially highlighted during the COVID-19 pandemic. Immunoassays continue to hold a strong position due to their affordability and effectiveness in large-scale screening, particularly through rapid tests like lateral flow assays. Emerging technologies such as next-generation sequencing (NGS) and biosensor-based diagnostics are increasingly being adopted in research and specialized clinical applications, reflecting a shift toward high-resolution and real-time diagnostics. Meanwhile, artificial intelligence and machine learning-driven platforms, though still in the early stages, are rapidly evolving and expected to play a transformative role in enhancing diagnostic accuracy and streamlining clinical decision-making.

**U.S. Infectious Respiratory Disease Diagnostics Market, By Disease Type**

* **COVID-19**
* **Influenza**
* **Tuberculosis**
* **Respiratory Syncytial Virus**
* **Pneumonia**
* **Other Respiratory Pathogens**

In the U.S. Infectious Respiratory Disease Diagnostics Market, COVID-19 has been a dominant driver, particularly during the pandemic, leading to significant advancements in diagnostic technologies and rapid testing solutions. Following closely in importance is influenza, with annual seasonal outbreaks prompting ongoing demand for effective diagnostic tools, especially for rapid antigen and PCR tests. Tuberculosis continues to be A close-up of hands holding a tablet and a pen

Description automatically generateda priority, particularly in high-risk populations, requiring diagnostic innovations focused on speed and accuracy, such as molecular-based tests. The Respiratory Syncytial Virus (RSV), a major concern for infants and elderly individuals, also sees strong demand for diagnostics, particularly during peak seasonal occurrences. Pneumonia, often associated with bacterial and viral pathogens, remains a critical area for diagnostic advancements to identify specific causative agents and guide treatment. Additionally, diagnostics for other respiratory pathogens, including those responsible for bronchitis, adenovirus infections, and parainfluenza, are steadily gaining attention, with multiplex testing solutions allowing for broader pathogen identification in single tests.

**U.S. Infectious Respiratory Disease Diagnostics Market, By End User**

* **Hospitals and Clinics**
* **Diagnostic Laboratories**
* **Home Care Settings**
* **Public Health Agencies**

In the U.S. Infectious Respiratory Disease Diagnostics Market, hospitals and clinics remain the largest end-user segment. Diagnostic laboratories follow closely, playing a crucial role in providing advanced testing solutions for a wide array of respiratory pathogens, especially with the growing demand for molecular and multiplex testing. The home care settings segment is gaining momentum, fueled by the increasing preference for at-home testing kits and remote health monitoring, particularly for non-critical patients who require quick and convenient diagnostic options. Meanwhile, public health agencies are instrumental in the surveillance and control of infectious respiratory diseases, driving the adoption of large-scale diagnostic solutions for screening, epidemiological studies, and outbreak response.

**Key Players**

The “U.S. Infectious Respiratory Disease Diagnostics Market" study report will provide valuable insight emphasizing the U.S. market. The major players in the market Abbott, Roche, Thermo Fisher Scientific, Siemens Healthineers, Danaher Corporation, Cepheid, PerkinElmer, Hologic, Quidel Corporation, Illumina, Medtronic, Grifols, Bio-Rad A close-up of hands holding a tablet and a pen

Description automatically generatedLaboratories, Luminex Corporation, GenMark Diagnostics, Becton, Dickinson and Company among others. Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

**Key Developments**

* In 2024, Roche received FDA Emergency Use Authorization (EUA) for its cobas ® liat SARS-CoV-2, Influenza A/B & RSV test, an automated diagnostic tool that delivers rapid, accurate results in just 20 minutes.
* In 2024, Shionogi & Co., Ltd. received FDA Fast Track designation for **S-337395**, an oral antiviral drug aimed at treating respiratory syncytial virus (RSV).

**Market Attractiveness**

The image of market attractiveness provided further helps to get information about the region leading in the U.S. Infectious Respiratory Disease Diagnostics Market. We cover the major impacting factors driving the industry growth in the given region.

**Porter’s Five Forces**

The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape U.S. Infectious Respiratory Disease Diagnostics Market, gauge the attractiveness of a particular sector, and assess investment possibilities.

A close-up of hands holding a tablet and a pen

Description automatically generatedTABLE OF CONTENT

1 **INTRODUCTION OF** **U.S. INFECTIOUS RESPIRATORY DISEASE DIAGNOSTICS MARKET**

* 1. Overview of the market
  2. Scope of report
  3. Assumptions

1. **EXECUTIVE SUMMARY**
2. **RESEARCH METHODOLOGY**
   1. Data Mining
   2. Validation
   3. Primary Interviews
   4. List of Data sources
3. **U.S. INFECTIOUS RESPIRATORY DISEASE DIAGNOSTICS MARKET OUTLOOK**
   1. Overview
   2. Market Dynamics
      1. Drivers
      2. Restrains
      3. Opportunities
      4. Trends
   3. Portes Five FORCE Model
   4. Value Chain Analysis

**5 U.S. INFECTIOUS RESPIRATORY DISEASE DIAGNOSTICS MARKET**, **BY TECHNOLOGY**

5.1 Overview

A close-up of hands holding a tablet and a pen

Description automatically generated5.2 Molecular Diagnostics

5.3 Immunoassays

5.4 Microbiological Culture Techniques

5.5 Biosensors and Nanotechnology-Based Diagnostics

5.6 Next-Generation Sequencing (NGS)

5.7 Artificial Intelligence and Machine Learning-Based Platforms

**6 U.S. INFECTIOUS RESPIRATORY DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE**

6.1 Overview

6.2 COVID-19

6.3 Influenza

6.4 Tuberculosis

6.5 Respiratory Syncytial Virus

6.6 Pneumonia

6.7 Other Respiratory Pathogens

**7** **U.S. INFECTIOUS RESPIRATORY DISEASE DIAGNOSTICS MARKET, BY END USER**

7.1 Overview

7.2 Hospitals and Clinics

7.3 Diagnostic Laboratories

7.4 Home Care Settings

A close-up of hands holding a tablet and a pen

Description automatically generated 7.5 Public Health Agencies

1. **U.S. INFECTIOUS RESPIRATORY DISEASE DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE**
   1. Overview
   2. Company Market Ranking
   3. Key Developments Strategies
2. **COMPANY PROFILES**

**9.1 Abbott**

* + 1. Overview
    2. Financial Performance
    3. Product Outlook
    4. Key developments
  1. **Roche**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Thermo Fisher Scientific**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **Siemens Healthineers**
     1. A close-up of hands holding a tablet and a pen

        Description automatically generatedOverview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **Danaher Corporation**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **Cepheid**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  6. **PerkinElmer**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **Hologic**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments

* 1. **Quidel Corporation**
     1. A close-up of hands holding a tablet and a pen

        Description automatically generatedOverview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Illumina**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **Medtronic**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **Grifols**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **Bio-Rad Laboratories**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  6. **Luminex Corporation**
     1. Overview
     2. A close-up of hands holding a tablet and a pen

        Description automatically generatedFinancial Performance
     3. Product Outlook
     4. Key developments
  7. **GenMark Diagnostics**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  8. **Becton, Dickinson and Company**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments

1. **KEY DEVELOPMENTS**
   1. Product Launches/Developments
   2. Merges and Acquisitions
   3. Business Expansions
   4. Partnerships and Collaborations
2. **Appendix**

11.1 Related Research